
Repetitive therapy with indirect laser and pharmacotherapy in paediatric Coats disease: Long-term follow up of two clinical cases. Maria Emfietzoglou¹, Maria-Emma Savvidou¹, Alexander Charonis¹

1. Retina Service, Athens Vision Eye Institute, Athens

- <u>Aim:</u> Analysis of two cases and review of the pertinent literature.
- Materials/Methods: Case series.
- Results (1): We studied two eyes of two young boys (2-and 6-year-old) who underwent repeat sessions of indirect laser ablation, intravitreal therapy with bevacizumab and orbital floor triamcinolone injection for stage 3 Coats disease.





• Results (2): We observed satisfactory, albeit slow, resolution of the exudative detachment and the abnormal retinal vasculature with improvement of the BCVA to 20/60, in 4 and 14 years of follow-up respectively.

	Clinical Characteristics	
	Case 1	Case 2
Age at presentation	2 years	7 years
Baseline BCVA	CF	20/250
Last BCVA	20/60	20/60
Follow-up	4 years	14 years

	Treatment Burden		
	Case 1	Case 2	
PRP			
- Sessions	14	4	
- Burns	3650	1800	
Injections			
- Bevacizumab	9	6	
- Triamcinolone	4	2	

• Conclusions: Repeat, combined therapy with indirect laser ablation and pharmacotherapy achieves satisfactory long-term regression of the disease. The therapeutic load remains significant, especially among cases with early diagnosis.





References:

- Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of Coats disease. Surv Ophthalmol. 2014 Jan-Feb;59(1):30-46. doi: 10.1016/j.survophthal.2013.03.007.
- Belin PJ, Lee AC, Greaves G, Kosoy J, Lieberman RM. The use of bevacizumab in pediatric retinal and choroidal disease: A review. Eur J Ophthalmol. 2019 May;29(3):338-347.
- Shieh WS, Shah GK, Blinder KJ. Coats' Disease-Related Macular Edema Treated with Combined Aflibercept and Laser Photocoagulation. Case Rep Ophthalmol Med. 2017;2017:2824874.
- Mastropasqua R, D'Aloisio R, Stanga PE, Haynes R. Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up. J Ophthalmol. 2020 Oct 26;2020:8840630.

Athens Vision